• Veracyte flagged new phase III data for its Prosigna Breast test in the OPTIMA trial, with results scheduled for presentation at the ASCO annual meeting in Chicago on May 30, 2026.
• The company positioned the findings as supporting Prosigna-guided decisions on adjuvant chemotherapy in high clinical-risk, early-stage breast cancer, aiming to help clinicians identify patients who can safely avoid chemotherapy.
• Separate ENZAMET phase III analyses tied to the Decipher Prostate test are also due at ASCO on May 30, 2026, framing the test as a tool to identify metastatic prostate cancer patients most likely to benefit from treatment intensification while steering others away from unnecessary chemotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605211800BIZWIRE_USPR_____20260521_BW430337) on May 21, 2026, and is solely responsible for the information contained therein.